CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) dropped 2.1% on Tuesday . The company traded as low as $0.2230 and last traded at $0.2304. Approximately 2,577,568 shares changed hands during mid-day trading, an increase of 39% from the average daily volume of 1,859,706 shares. The stock had previously closed at $0.2354.
CytoDyn Stock Up 4.4%
The stock has a market cap of $330.54 million, a price-to-earnings ratio of -8.00 and a beta of 1.16. The company’s 50-day moving average is $0.29 and its 200-day moving average is $0.28.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel immunotherapies. The company’s lead product candidate, leronlimab (PRO 140), is a humanized monoclonal antibody designed to block the CCR5 receptor, which plays a critical role in HIV infection and certain cancer pathways. CytoDyn is advancing leronlimab through multiple clinical trials targeting indications such as treatment-resistant HIV, metastatic triple-negative breast cancer, and other oncology and inflammatory conditions.
In its pursuit of regulatory approvals, CytoDyn has conducted Phase II and Phase III studies of leronlimab in people living with HIV who have experienced virologic failure on existing therapies.
Read More
- Five stocks we like better than CytoDyn
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
